These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Management of overactive bladder syndrome. Srikrishna S; Robinson D; Cardozo L; Vella M Postgrad Med J; 2007 Jul; 83(981):481-6. PubMed ID: 17621619 [TBL] [Abstract][Full Text] [Related]
6. New developments in the medical management of overactive bladder. Robinson D; Giarenis I; Cardozo L Maturitas; 2013 Nov; 76(3):225-9. PubMed ID: 23953245 [TBL] [Abstract][Full Text] [Related]
7. Overactive bladder syndrome - management and treatment options. Arnold J; McLeod N; Thani-Gasalam R; Rashid P Aust Fam Physician; 2012 Nov; 41(11):878-83. PubMed ID: 23145420 [TBL] [Abstract][Full Text] [Related]
12. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy. Liu HT; Lin H; Kuo HC Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder. Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844 [TBL] [Abstract][Full Text] [Related]
14. Current management and future perspectives of overactive bladder (OAB) pharmacotherapy. Dobrek Ł; Juszczak K; Wyczółkowski M; Thor PJ Acta Pol Pharm; 2011; 68(6):807-21. PubMed ID: 22125944 [TBL] [Abstract][Full Text] [Related]
15. Fesoterodine: a new agent for treating overactive bladder. Ellsworth P; Berriman SJ; Brodsky M Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800 [TBL] [Abstract][Full Text] [Related]
16. Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial. Burgio KL; Goode PS; Johnson TM; Hammontree L; Ouslander JG; Markland AD; Colli J; Vaughan CP; Redden DT J Am Geriatr Soc; 2011 Dec; 59(12):2209-16. PubMed ID: 22092152 [TBL] [Abstract][Full Text] [Related]
17. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes. Garely AD; Lucente V; Vapnek J; Smith N Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526 [TBL] [Abstract][Full Text] [Related]
18. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014 [TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. Cardozo L; Thorpe A; Warner J; Sidhu M BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]